7 results
Primary:* To prove the superiority of a 48-weeks treatment with 3.2 g/day delayedreleasephosphatidylcholine (LT-02) versus placebo for the maintenance ofremission in patients with ulcerative colitis (UC)Secondary:* To study safety and tolerability…
To assess the analgesic effect of ARA290 in chronic pain patients
To investigate the clinical pharmacokinetics of tobramycin and/or colistin after nasal administration. With this pharmacokinetic parameters the safety of this treatment can be investigated.
To measure the plasma conc. of ARA 290 in healthy volunteers
To measure the PK of ARA290 when given in de SQ form
In this study we will assess the effect of ARA290 on nerve damage by taking 4 skin bipsies during treatment.
ARA290 is a new drug against neuropathic pain and was succesfully tested in previous studies on patients with neuropathic pain due to diabetes and sarcoidosis. The current study involves sarcoidosis patients with pain due to neuropathy. The purpose…